학술논문

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY.
Document Type
Article
Source
Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-3, 3p
Subject
Language
ISSN
02780232